The Pathogenesis of Superior Limbic Keratoconjunctivitis

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.

Verified June 2005 by National Taiwan University Hospital.
Recruitment status was: Recruiting

Sponsor:

Information provided by:

National Taiwan University Hospital

ClinicalTrials.gov Identifier:

NCT00167050

First received: September 12, 2005

Last updated: November 25, 2005

Last verified: June 2005

History of Changes

Purpose

Superior limbic keratoconjunctivitis (SLK) was first described in detail as a clinical entity by Frederick Theodore in 1963. The clinical picture of SLK is well documented, but the etiology is still unknown. This project will be conducted into through two parts: one is to investigate the presentation of chemokine receptors on mast cell and matrix metalloproteinases on fibroblasts by immunohistochemistry method from the pathological specimens of SLK patients who received conjunctiva resection as the treatment. The other part is to investigate the mRNA level of those chemokine receptors via reverse transcription - polymerase chain reaction from the conjunctiva collecting form SLK patients.

Condition
Superior Limbic Keratoconjunctivitis


Study Type:	Observational
Study Design:	Observational Model: Defined Population Observational Model: Natural History Time Perspective: Cross-Sectional Time Perspective: Prospective

Resource links provided by NLM:

Genetic and Rare Diseases Information Center resources: Superior Limbic Keratoconjunctivitis

U.S. FDA Resources

Further study details as provided by National Taiwan University Hospital:


Estimated Enrollment:	10
Study Start Date:	July 2005
Estimated Study Completion Date:	June 2006

Show Detailed Description

Eligibility


Ages Eligible for Study:	20 Years to 80 Years (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Superior limbic keratoconjunctivitis patients who receive conjunctiva resection

Exclusion Criteria:

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00167050

Contacts


Contact: Fung-Rong Hu, MD	886-2-23123456 ext 5189	fungrong@ha.mc.ntu.edu.tw
Contact: Yi-Chen Sun, MD	886-968195019	yichen.sun@msa.hinet.net

Locations


Taiwan
National Taiwan University Hospital	Recruiting
Taipei, Taiwan
Contact: Fung-Rong Hu, MD 886-2-23123456 ext 5189 fungrong@ha.mc.ntu.edu.tw
Contact: Yi-Chen Sun, MD 886-968195019 yichen.sun@msa.hinet.net
Principal Investigator: Fung-Rong Hu, MD

Sponsors and Collaborators

National Taiwan University Hospital

Investigators


Principal Investigator:	Fung-Rong Hu, MD	National Taiwan University Hospital

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Sun YC, Hsiao CH, Chen WL, Hu FR. Overexpression of matrix metalloproteinase-1 (MMP-1) and MMP-3 in superior limbic keratoconjunctivitis. Invest Ophthalmol Vis Sci. 2011 Jun 1;52(6):3701-5. doi: 10.1167/iovs.10-6324.

Sun YC, Hsiao CH, Chen WL, Wang IJ, Hou YC, Hu FR. Conjunctival resection combined with tenon layer excision and the involvement of mast cells in superior limbic keratoconjunctivitis. Am J Ophthalmol. 2008 Mar;145(3):445-452. doi: 10.1016/j.ajo.2007.10.025. Epub 2008 Jan 16.


ClinicalTrials.gov Identifier:	NCT00167050 History of Changes
Other Study ID Numbers:	9461700634
Study First Received:	September 12, 2005
Last Updated:	November 25, 2005

Additional relevant MeSH terms:


Keratoconjunctivitis Conjunctivitis Conjunctival Diseases	Eye Diseases Keratitis Corneal Diseases

ClinicalTrials.gov processed this record on June 22, 2017

To Top